A phase II study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience

Ryan H. Engel, Jennifer A. Brown, Jamie H. Von Roenn, Ruth M. O'Regan, Raymond Bergan, Sunil Badve, Alfred Rademaker, William J. Gradishar

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

PS-341, now known as bortezomib (Velcade[Millenium Pharmaceuticals, Inc., Cambridge, MA; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring house, PA]), is a proteasome inhibitor approved for the treatment of refractory multiple myeloma. Preclinical and early clinical studies showed PS-341 to be effective in solid tumors, one of which was breast cancer. We conducted a single institution, phase II study using PS-341 in the treatment of patients with metastatic breast cancer. The primary objective of this study was to determine the objective tumor response in patients with metastatic breast cancer (MBC) receiving PS-341. The secondary objectives were to estimate progression-free survival of patients receiving single-agent PS-341 and to evaluate toxicity related to PS-341. In all 12 patients who met criteria for enrollment, there were no observed objective responses. Further, all 12 patients progressed while receiving therapy with PS-341. This study was terminated after the first stage due to the lack of any objective response.

Original languageEnglish (US)
Pages (from-to)733-737
Number of pages5
JournalCancer Investigation
Volume25
Issue number8
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Breast Neoplasms
Bortezomib
Proteasome Inhibitors
Multiple Myeloma
Disease-Free Survival
Neoplasms
Therapeutics
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Bortezomib
  • Breast cancer
  • Iκβ
  • NFκβ
  • Proteasome
  • PS-341

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II study of single agent bortezomib in patients with metastatic breast cancer : A single institution experience. / Engel, Ryan H.; Brown, Jennifer A.; Von Roenn, Jamie H.; O'Regan, Ruth M.; Bergan, Raymond; Badve, Sunil; Rademaker, Alfred; Gradishar, William J.

In: Cancer Investigation, Vol. 25, No. 8, 12.2007, p. 733-737.

Research output: Contribution to journalArticle

Engel, RH, Brown, JA, Von Roenn, JH, O'Regan, RM, Bergan, R, Badve, S, Rademaker, A & Gradishar, WJ 2007, 'A phase II study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience', Cancer Investigation, vol. 25, no. 8, pp. 733-737. https://doi.org/10.1080/07357900701506573
Engel, Ryan H. ; Brown, Jennifer A. ; Von Roenn, Jamie H. ; O'Regan, Ruth M. ; Bergan, Raymond ; Badve, Sunil ; Rademaker, Alfred ; Gradishar, William J. / A phase II study of single agent bortezomib in patients with metastatic breast cancer : A single institution experience. In: Cancer Investigation. 2007 ; Vol. 25, No. 8. pp. 733-737.
@article{c57052ddf54e4678b2eb98ca9f6bb9f2,
title = "A phase II study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience",
abstract = "PS-341, now known as bortezomib (Velcade[Millenium Pharmaceuticals, Inc., Cambridge, MA; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring house, PA]), is a proteasome inhibitor approved for the treatment of refractory multiple myeloma. Preclinical and early clinical studies showed PS-341 to be effective in solid tumors, one of which was breast cancer. We conducted a single institution, phase II study using PS-341 in the treatment of patients with metastatic breast cancer. The primary objective of this study was to determine the objective tumor response in patients with metastatic breast cancer (MBC) receiving PS-341. The secondary objectives were to estimate progression-free survival of patients receiving single-agent PS-341 and to evaluate toxicity related to PS-341. In all 12 patients who met criteria for enrollment, there were no observed objective responses. Further, all 12 patients progressed while receiving therapy with PS-341. This study was terminated after the first stage due to the lack of any objective response.",
keywords = "Apoptosis, Bortezomib, Breast cancer, Iκβ, NFκβ, Proteasome, PS-341",
author = "Engel, {Ryan H.} and Brown, {Jennifer A.} and {Von Roenn}, {Jamie H.} and O'Regan, {Ruth M.} and Raymond Bergan and Sunil Badve and Alfred Rademaker and Gradishar, {William J.}",
year = "2007",
month = "12",
doi = "10.1080/07357900701506573",
language = "English (US)",
volume = "25",
pages = "733--737",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - A phase II study of single agent bortezomib in patients with metastatic breast cancer

T2 - A single institution experience

AU - Engel, Ryan H.

AU - Brown, Jennifer A.

AU - Von Roenn, Jamie H.

AU - O'Regan, Ruth M.

AU - Bergan, Raymond

AU - Badve, Sunil

AU - Rademaker, Alfred

AU - Gradishar, William J.

PY - 2007/12

Y1 - 2007/12

N2 - PS-341, now known as bortezomib (Velcade[Millenium Pharmaceuticals, Inc., Cambridge, MA; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring house, PA]), is a proteasome inhibitor approved for the treatment of refractory multiple myeloma. Preclinical and early clinical studies showed PS-341 to be effective in solid tumors, one of which was breast cancer. We conducted a single institution, phase II study using PS-341 in the treatment of patients with metastatic breast cancer. The primary objective of this study was to determine the objective tumor response in patients with metastatic breast cancer (MBC) receiving PS-341. The secondary objectives were to estimate progression-free survival of patients receiving single-agent PS-341 and to evaluate toxicity related to PS-341. In all 12 patients who met criteria for enrollment, there were no observed objective responses. Further, all 12 patients progressed while receiving therapy with PS-341. This study was terminated after the first stage due to the lack of any objective response.

AB - PS-341, now known as bortezomib (Velcade[Millenium Pharmaceuticals, Inc., Cambridge, MA; and Johnson & Johnson Pharmaceutical Research & Development, LLC, Spring house, PA]), is a proteasome inhibitor approved for the treatment of refractory multiple myeloma. Preclinical and early clinical studies showed PS-341 to be effective in solid tumors, one of which was breast cancer. We conducted a single institution, phase II study using PS-341 in the treatment of patients with metastatic breast cancer. The primary objective of this study was to determine the objective tumor response in patients with metastatic breast cancer (MBC) receiving PS-341. The secondary objectives were to estimate progression-free survival of patients receiving single-agent PS-341 and to evaluate toxicity related to PS-341. In all 12 patients who met criteria for enrollment, there were no observed objective responses. Further, all 12 patients progressed while receiving therapy with PS-341. This study was terminated after the first stage due to the lack of any objective response.

KW - Apoptosis

KW - Bortezomib

KW - Breast cancer

KW - Iκβ

KW - NFκβ

KW - Proteasome

KW - PS-341

UR - http://www.scopus.com/inward/record.url?scp=36849013003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849013003&partnerID=8YFLogxK

U2 - 10.1080/07357900701506573

DO - 10.1080/07357900701506573

M3 - Article

C2 - 17952740

AN - SCOPUS:36849013003

VL - 25

SP - 733

EP - 737

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 8

ER -